Welcome to the international HTA database

Showing [16733 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2009	Blue Cross Blue Shield Association (BCBS)	Accelerated radiotherapy after breast-conserving surgery for early stage breast cancer
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of hydromyelia in adults: a review of clinical effectiveness and guidelines
2009	NIHR Health Technology Assessment programme	Continuous positive airways pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome (OSAHS)
2009	NIHR Health Technology Assessment programme	Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Indacaterol (Onbrez Breezhaler) for chronic obstructive pulmonary disease
2009	Health Intervention and Technology Assessment Program (HITAP)	The potential of provider-initiated voluntary HIV counseling and testing at health care settings in Thailand
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Reassessment of health technologies: obsolescence and waste
2009	Blue Cross Blue Shield Association (BCBS)	Special report: laboratory testing to allow area under the curve (AUC) - targeted 5-Fluorouracil dosing for patients administered chemotherapy for cancer
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Surgical dental interventions for use in children and adults: a review of the comparative clinical and cost-effectiveness
2009	NIHR Health Technology Assessment programme	The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model
2009	NIHR Health Technology Assessment programme	Endovascular stents for abdominal aortic aneurysms
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ofatumumab for follicular non-Hodgkin's lymphoma - refractory
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE
2009	Blue Cross Blue Shield Association (BCBS)	Genetic testing for predisposition to inherited hypertrophic cardiomyopathy
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cardiac Magnetic Resonance Imaging (MRI) for patients with coronary artery disease: a review of diagnostic accuracy
2009	Norwegian Knowledge Centre for the Health Services (NOKC)	Rehabilitation of breast cancer patients
2009	NIHR Health Technology Assessment programme	Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation
2009	NIHR Health Technology Assessment programme	The effectiveness and cost-effectiveness of machine perfusion systems and cold static storage of donated kidneys
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Patupilone (EPO906) for recurrent epithelial ovarian cancer - refractory and/or resistant
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-Acting Beta2-Agonist and Inhaled Corticosteroid Combination Therapy for Adult Persistent Asthma: Systematic Review of Clinical Outcomes and Economic Evaluation
2009	Blue Cross Blue Shield Association (BCBS)	Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Multi-slice computed tomography coronary angiography for coronary artery disease: a review of the clinical effectiveness and guidelines
2009	NIHR Health Technology Assessment programme	Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation
2009	NIHR Health Technology Assessment programme	Infliximab for the treatment of adults with psoriasis
2009	NIHR Health Technology Assessment programme	Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Pirfenidone for idiopathic pulmonary fibrosis
2009	Blue Cross Blue Shield Association (BCBS)	Pharmacogenetic testing to predict serious toxicity from 5-Fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Follow-up to 'The role of pharmacologic management in neovascular age- related macular degeneration: clinical and cost-effectiveness'
2009	NIHR Health Technology Assessment programme	Zanamivir, oseltamivir and amantadine for the treatment of influenza (an update review of existing guidance)
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Quetiapine (Seroquel XL) for major depressive disorder
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Indirect calorimetry to measure energy requirements: a review of the guidelines and clinical effectiveness
2009	NIHR Health Technology Assessment programme	Lapatinib for the treatment of HER2-overexpressing breast cancer
2009	NIHR Health Technology Assessment programme	Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ranibizumab (Lucentis) for macular oedema secondary to central or branch retinal vein occlusion
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	C-reactive protein levels for cardiovascular disease screening: a review of accuracy, use, and guidelines
2009	NIHR Health Technology Assessment programme	Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2009	NIHR Health Technology Assessment programme	Enhanced external counterpulsation for stable angina or heart failure: a systematic review and economic evaluation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ranibizumab (Lucentis) for diabetic macular oedema
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Chiropractic interventions for acute or chronic lower back pain in adults: a review of the clinical and cost-effectiveness
2009	NIHR Health Technology Assessment programme	Rimonabant for the treatment of overweight and obese people
2009	NIHR Health Technology Assessment programme	Non-occupational post-exposure prophylaxis for HIV
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Retigabine for partial onset epilepsy - refractory
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Alvimopan for surgical patients: a review of the clinical and cost-effectiveness
2009	NIHR Health Technology Assessment programme	Infliximab for the treatment of ulcerative colitis
2009	NIHR Health Technology Assessment programme	The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Sativex for adults experiencing pain from cancer
2009	NIHR Health Technology Assessment programme	Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Vinflunine (Javlor) for transitional cell carcinoma of the urothelial tract - second line
2009	NIHR Health Technology Assessment programme	Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal
2009	HAYES, Inc.	Saw palmetto for benign prostatic hyperplasia
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Afamelanotide for erythropoietic protoporphyria and congenital erythropoietic porphyria
2009	NIHR Health Technology Assessment programme	A systematic review of presumed consent systems for deceased organ donation
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Alipogene tiparvovec (AMT-011, Glybera) for lipoprotein lipase deficiency
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Clopidogrel (Plavix) for neonates and infants with cyanotic congenital heart disease who have undergone a palliative shunt procedure
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ofatumumab for fludarabine-refractory chronic lymphocytic leukaemia - second or third-line
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Omalizumab (Xolair) for severe persistent allergic asthma in children
2009	University of York	A systematic review of risk prediction rules in febrile neutropenic episodes in children and young people undergoing treatment for malignant disease (Protocol for a systematic review)
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Silodosin for benign prostatic hyperplasia
2009	HAYES, Inc.	Spinal cord stimulation for relief of neuropathic pain
2009	Medical Advisory Secretariat (MAS)	Specialized multidisciplinary community-based care series: summary of evidence-based analyses
2009	HAYES, Inc.	Stereotactic radiosurgery for arteriovenous malformations and intracranial tumors
2009	NIHR Horizon Scanning Centre (NIHR HSC)	WATCHMAN left atrial appendage (LAA) closure device for non-valvular atrial fibrillation (AF)
2009	Medical Advisory Secretariat (MAS)	Diabetes strategy evidence platform: summary of evidence-based analyses
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Agento I.C for ventilator associated pneumonia
2009	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Fast-track surgery and enhanced recovery after surgery (ERAS) programs
2009	Medical Advisory Secretariat (MAS)	Prevention and management of pressure ulcers: summary of evidence-based analyses
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Radachlorin photodynamic therapy for basal cell carcinoma
2009	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic thoracic sympathectomy
2009	Medical Advisory Secretariat (MAS)	Intraocular lenses for the treatment of age-related cataracts: an evidence-based analysis
2009	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Neoadjuvant radiochemotherapy for rectal cancer
2009	Medical Advisory Secretariat (MAS)	Phakic intraocular lenses for the treatment of low to high refractive errors: an evidence-based analysis
2009	Belgian Health Care Knowledge Centre (KCE)	Interspinous implants and pedicle screws for dynamic stabilization of lumbar spine: Rapid assessment
2009	Medical Advisory Secretariat (MAS)	Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis
2009	Medical Advisory Secretariat (MAS)	Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis
2009	Medical Advisory Secretariat (MAS)	Oral appliances for obstructive sleep apnea: an evidence-based analysis
2009	NIHR Health Technology Assessment programme	Adalimumab for the treatment of moderate to severe psoriatic arthritis
2009	Medical Advisory Secretariat (MAS)	Fenestrated endovascular grafts for the repair of juxtarenal aortic aneurysms: an evidence-based analysis
2009	Medical Advisory Secretariat (MAS)	OHTAC 2009 Progress Report - advancing health: evidence-based advice on health technology
2009	Medical Advisory Secretariat (MAS)	Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis
2009	Quality Improvement Scotland (NHS QIS )	Is patient self-monitoring (including self-testing and selfmanagement) of oral anticoagulation therapy safe, efficacious and cost-effective?
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Early term induction of labor
2009	Quality Improvement Scotland (NHS QIS )	Provision of information to patients with long term conditions
2009	Quality Improvement Scotland (NHS QIS )	A systematic narrative review of quality improvement models in health care
2009	HAYES, Inc.	Intravitreal bevacizumab (Avastin; Genentech Inc.) for the treatment of proliferative diabetic retinopathy
2009	Quality Improvement Scotland (NHS QIS )	Clinical and cost-effectiveness of self-monitoring of blood glucose (SMBG) for non-insulin treated type 2 diabetes
2009	VA Technology Assessment Program (VATAP)	Systematic reviews for localized prostate cancer
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Is biomedical research a good social investment? The evaluation of the social impact of medical research
2009	HAYES, Inc.	Breast-specific gamma imaging (BSGI)
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Multiple chemical hypersensibility: state of the art on aetiology and treatment
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®) for the treatment of HIV-1 infected, treatment-naïve adults in combination with other antiretroviral medicinal products
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Amotosalen (Intercept) for the inactivation of pathogens in plasma and platelets: usage in Spain
2009	HAYES, Inc.	Laparoscopic ileal interposition and sleeve gastrectomy for treatment of type 2 diabetes [REVISED 02.16.09]
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Degarelix (Firmagon®) for the treatment of advanced hormone-dependent prostate cancer
2009	HAYES, Inc.	Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig Disease)
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Reprocessing of surgical drills
2009	Penn Medicine Center for Evidence-based Practice (CEP)	Managing the difficult airway
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ranolazine (Ranexa®) as add-on therapy for symptomatic treatment of stable angina pectoris
2009	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Emerging technologies (part 2): EU newsletter
2009	HAYES, Inc.	Laparoscopic sleeve gastrectomy for super obesity in adults
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Methoxy polyethylene glycol-epoetin beta (Mircera®)